Literature DB >> 24010963

Melanoma-associated leukoderma - immunology in black and white?

Hadas Prag Naveh1, Uma N M Rao, Lisa H Butterfield.   

Abstract

Melanoma is an 'immunogenic tumor', often highly infiltrated with lymphocytes, which are capable of inducing regression of the primary tumor. The commonly observed phenomenon of regression suggests substantial cross-talk between immune cells and transformed melanocytes. An immune response to melanocyte differentiation antigens common to transformed and normal melanocytes manifests clinically at distant sites as melanoma-associated vitiligo or halo nevi. Despite similar antigenic targets, the pathogenesis and prognosis differ between the different melanoma-associated leukodermas. Understanding immunologic cross-talk between melanocytes and the immune system will aid the development of approaches to combat melanoma.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  immunity; leukoderma; melanocyte; melanoma; nevus; vitiligo

Mesh:

Year:  2013        PMID: 24010963      PMCID: PMC3855876          DOI: 10.1111/pcmr.12161

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  66 in total

1.  Subcellular localization of the melanoma-associated protein Melan-AMART-1 influences the processing of its HLA-A2-restricted epitope.

Authors:  D Rimoldi; K Muehlethaler; S Salvi; D Valmori; P Romero; J C Cerottini; F Levy
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

2.  Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.

Authors:  Hensin Tsao; Peri Millman; Gerald P Linette; F Stephen Hodi; Arthur J Sober; Mark A Goldberg; Frank G Haluska
Journal:  Arch Dermatol       Date:  2002-06

3.  Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.

Authors:  J C Becker; P Guldberg; J Zeuthen; E B Bröcker; P T Straten
Journal:  J Invest Dermatol       Date:  1999-12       Impact factor: 8.551

4.  The natural history of halo nevi: a retrospective case series.

Authors:  Mouhammad Aouthmany; Mara Weinstein; Matthew J Zirwas; Robert T Brodell
Journal:  J Am Acad Dermatol       Date:  2012-03-02       Impact factor: 11.527

Review 5.  Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".

Authors:  W W Overwijk; N P Restifo
Journal:  Crit Rev Immunol       Date:  2000       Impact factor: 2.214

6.  Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment?

Authors:  Silvia Moretti; Adelina Spallanzani; Cinzia Pinzi; Francesca Prignano; Paolo Fabbri
Journal:  J Cutan Pathol       Date:  2007-04       Impact factor: 1.587

7.  Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases.

Authors:  Joan Guitart; Lori Lowe; Michael Piepkorn; Victor G Prieto; Michael S Rabkin; Salve G Ronan; Christopher R Shea; Victor A Tron; Wain White; Raymond L Barnhill
Journal:  Arch Dermatol       Date:  2002-05

8.  Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis.

Authors:  H E Teulings; E P M Tjin; K J Willemsen; G Krebbers; C J van Noesel; E H Kemp; L Nieuweboer-Krobotova; J P W van der Veen; R M Luiten
Journal:  Br J Dermatol       Date:  2013-02-27       Impact factor: 9.302

Review 9.  Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?

Authors:  Maya Ram; Yehuda Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

10.  Thymic selection generates a large T cell pool recognizing a self-peptide in humans.

Authors:  Alfred Zippelius; Mikaël J Pittet; Pascal Batard; Nathalie Rufer; Magda de Smedt; Philippe Guillaume; Kim Ellefsen; Danila Valmori; Danielle Liénard; Jean Plum; H Robson MacDonald; Daniel E Speiser; Jean-Charles Cerottini; Pedro Romero
Journal:  J Exp Med       Date:  2002-02-18       Impact factor: 14.307

View more
  11 in total

Review 1.  Pigmentation Disorders in the Elderly.

Authors:  Andrew M Armenta; Emily D Henkel; Ammar M Ahmed
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors.

Authors:  Alice Ramondetta; Simone Ribero; Luca Conti; Paolo Fava; Elena Marra; Paolo Broganelli; Virginia Caliendo; Franco Picciotto; Michele Guida; Maria Teresa Fierro; Pietro Quaglino
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

3.  Eruptive Halo Naevi: A Possible Indicator of Malignant Disease in a Case Series of Post-Adolescent Patients.

Authors:  Henrik F Lorentzen
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

Review 4.  Melanoma and Vitiligo: In Good Company.

Authors:  Cristina Maria Failla; Maria Luigia Carbone; Cristina Fortes; Gianluca Pagnanelli; Stefania D'Atri
Journal:  Int J Mol Sci       Date:  2019-11-15       Impact factor: 5.923

5.  Dermoscopy of halo nevus in own observation.

Authors:  Grażyna Kamińska-Winciorek; Jan Szymszal
Journal:  Postepy Dermatol Alergol       Date:  2014-06-13       Impact factor: 1.837

6.  Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.

Authors:  Andries Blokzijl; Lei E Chen; Sigrun M Gustafsdottir; Jimmy Vuu; Gustav Ullenhag; Olle Kämpe; Ulf Landegren; Masood Kamali-Moghaddam; Håkan Hedstrand
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

7.  Case of lymph node primary perivascular epithelioid cell tumor associated with leukoderma.

Authors:  Sachiko Tajima-Kondo; Yoshimasa Nobeyama; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2017-09-04       Impact factor: 4.005

8.  Two reports of malignant melanoma arising within a new vitiligo-like depigmented patch.

Authors:  Gina Francisco; Babar K Rao; Frank C Victor
Journal:  JAAD Case Rep       Date:  2018-06-12

9.  Local depigmentation as a sign of local recurrence of a histologic complete regressed malignant melanoma.

Authors:  Babette J A Verkouteren; Kristof E S Duthoi; Arjen M Rijken; Sarah J Caers
Journal:  JAAD Case Rep       Date:  2019-11-22

10.  Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report.

Authors:  Sonia Brugnara; Mariacristina Sicher; Elena Maria Bonandini; Mattia Barbareschi; Carlo Renè Girardelli; Orazio Caffo
Journal:  Drugs Context       Date:  2019-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.